Clinical Actions of l-Deprenyl in Parkinson’s Disease

  • M. D. Yahr
  • H. Kaufmann
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 88)


Over the past decade a number of investigators have reported on the usefulness of l-deprenyl, a selective inhibitor of monoamine oxidase type B (MAO-B) in the treatment of Parkinson’s disease. To a considerable extent these reports relate to its use as an adjunctive agent to levodopa administered when the therapeutic efficacy of the latter begins to diminish. More recently it has been suggested on theoretical grounds and in limited clinical experience that l-deprenyl may have a more valuable effect in being able to halt or retard the inexorable progressive nature of the underlying disease process of Parkinson’s disease. In this chapter, the clinical experience to date of the use of l-deprenyl in regard to its pharmacologic properties, indications for use, and effectiveness in the control of parkinsonism will be discussed.


Monoamine Oxidase Adjunctive Agent Monoamine Oxidase Type Parkinsonian State Brain Monoamine Oxidase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Barbeau A, Duchastel Y (1962) Tranylcypromine and the extrapyramidal syndrome. Can J Psychiatry 7: 91–95Google Scholar
  2. Bergmann KJ, Mendoza MR, Yahr MD (1986) Parkinson’s disease and long term levodopa therapy. In: Yahr MD, Bergmann K (eds) Advances in neurology, vol 45. Raven, New York p 463Google Scholar
  3. Bernheimer V, Birkmayer W, Horneykiewicz O (1962) Verhalten der Monoaminoxydase im Gehirn des Menschen nach Therapie mit Monoaminooxydase-Hämmern. Wien Klin Wochenschr 74: 558–559PubMedGoogle Scholar
  4. Birkmayer W, Riederer P, Youdim MBH, Linauer W (1975) The potentiation of the anti-akinetic effect after L-dopa treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm 36: 303–326PubMedCrossRefGoogle Scholar
  5. Birkmayer W, Riederer P, Ambrozi L, Youdim MBH (1977) Implications of combined treatment with Madopar and L-deprenyl in Parkinson’s disease. Lancet 2: 439–443CrossRefGoogle Scholar
  6. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J (1985) Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson’s disease: a long term study. J Neural Transm 64: 113–127PubMedCrossRefGoogle Scholar
  7. Blackwell B (1963) Hypertensive crisis due to monoamine-oxidase inhibitors. Lancet 2: 849–851PubMedCrossRefGoogle Scholar
  8. Cohen G (1983) The pathobiology of Parkinson’s disease: biochemical aspects of dopamine neuron senescence. J Neural Transm 19: 89–103Google Scholar
  9. Cohen G, Pasik P, Cohen B, Leist A, Mytilineou C, Yahr MD (1984) Pargyline and deprenyl prevent the neurotoxicity of l-methyl-4-phenyl-l,2,5,6,-tetrahydropyridine in monkeys. Eur J Pharmacol 106: 209–210PubMedCrossRefGoogle Scholar
  10. Csanda E, Tarczy M (1983) Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson’s disease. Acta Neurol Scand [Suppl] 95: 117–122CrossRefGoogle Scholar
  11. Csanda E, Antal J, Antony M, Csananaki (1978) Experiences with L-deprenyl in par¬kinsonism. J Neural Transm 43: 263–269PubMedCrossRefGoogle Scholar
  12. Ehringer H, Horneykiewicz O (1960) Verteilung von Noradrenalin und Dopamin im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Wien Klin Wochenschr 72: 1236Google Scholar
  13. Eisler T, Teravainen H, Nelson R, Krebs H et al. (1981) Deprenyl in Parkinson’s disease. Neurology 31: 19–23PubMedGoogle Scholar
  14. Eisworth JD, Glover V, Reynolds GP, Sandler M, Lees AJ, Phuapradit P, Shaw KM, Stern GM, Kumar P (1978) Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the “cheese effect”. Psychopharmacology (Berlin) 57: 33–38CrossRefGoogle Scholar
  15. Fahn S (1974) On-off phenomenon with levodopa therapy in parkinsonism. Neurology 24: 431–44PubMedGoogle Scholar
  16. Gerstenbrand F, Ransmayr G, Poewe W (1983) Deprenyl (selegeline) in combination treatment of Parkinson’s disease. Acta Neurol Scand [Suppl] 95: 123–126CrossRefGoogle Scholar
  17. Giovannini P, Grassi MP, Scigliano G, Piccolo I, Soliveri P, Caraceni T (1985) Deprenyl in Parkinson disease: personal experience. Ital J Neurol Sci 4: 207–212CrossRefGoogle Scholar
  18. Glover V, Sandler M, Owen F, Riley GJ (1977) Dopamine is a monoamine oxidase B substrate in man. Nature 265: 80–81PubMedCrossRefGoogle Scholar
  19. Goldstein L (1980) The “on-off” phenomena in Parkinson’s disease. Treatment and theoretical considerations. Mt Sinai J Med NY 47: 80–84Google Scholar
  20. Heikkila RL, Manzio L, Cabbat FS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of l-methyl-4-phenyl-l,2,5,6,-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311: 467–469PubMedCrossRefGoogle Scholar
  21. Horwitz D, Lovenberg W, Engelman K, Sjoerdsma A (1964) Monoamine oxidase inhibitors tyramine and cheese. JAMA 188: 1108–1110PubMedCrossRefGoogle Scholar
  22. Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17: 1285–1297PubMedCrossRefGoogle Scholar
  23. Knoll J (1978) The possible mechanisms of action of (-)-deprenyl in Parkinson’s disease. J Neural Transm 43: 177–198PubMedCrossRefGoogle Scholar
  24. Knoll J, Magyar K (1972) Some puzzling effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 5: 393–408PubMedGoogle Scholar
  25. Knoll J, Vizi ES, Somogyi G (1968) Phenylisopropylmethylpropinylamine (E-250), a monoamine oxidase inhibitor antagonizing the effects of tyramine. Arzneimittelforschung 18: 109Google Scholar
  26. Langston JW, Ballard P, Tetrud JW, Irwin IJ (1983) Chronic parkinsonism in humans due to a product of meperidine analog synthesis. Science 219: 979–980PubMedCrossRefGoogle Scholar
  27. Lees AJ, Shaw KM, Kohout LJ, Stern GM, Elsworth JD, Sandler M, Youdim MBH (1977) Deprenyl in Parkinson’s disease. Lancet 2: 791–796PubMedCrossRefGoogle Scholar
  28. Marsden CD, Parkes JD (1976) “On-off” effect in patients with Parkinson’s disease on chronic levodopa therapy. Lancet 1:292–296PubMedCrossRefGoogle Scholar
  29. Marsden CD, Parkes JD (1977) Success and problems of chronic levodopa therapy in Parkinson’s disease. Lancet 1: 345–349PubMedCrossRefGoogle Scholar
  30. McDowell FH, Sweet RD (1976) The on-off phenomenon. In: Birkmayer W, Horneykiewicz O (eds) Advances in parkinsonism. Roche, Basel, pp 603–612Google Scholar
  31. Moore KE (1977) The actions of amphetamine on neurotransmitters. Biol Psychiatry 12: 451–462PubMedGoogle Scholar
  32. Murphy DL, Wright C, Buchsbaum M et al. (1976) Platelet and plasma amine oxidase activity in 680 normals: sex and age differences and stability over time. Biochem Med Metab Biol 16: 254–265Google Scholar
  33. Presthus J, Hajba A (1983) Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson’s disease. Acta Neurol Scand [Suppl] 95: 127–133CrossRefGoogle Scholar
  34. Reynolds GP, Eisworth JD, Blau K, Sandler M, Lees AJ, Stern GM (1978) Deprenyl is metabolized to metamphetamine and amphetamine in man. Br J Clin Pharmacol 6: 542–544PubMedGoogle Scholar
  35. Rinne UK (1983) Deprenyl (selegiline) in the treatment of Parkinson’s disease. Acta Neurol Scand [Suppl] 95: 107–111CrossRefGoogle Scholar
  36. Rinne UK, Siirtola T, Sonninen V (1978) L-Deprenyl treatment of on-off phenomena in Parkinson’s disease. J Neural Transm 43: 253–262PubMedCrossRefGoogle Scholar
  37. Sandler M, Glover V, Ashford A, Stern GM (1978) Absence of “cheese effect” during deprenyl therapy: some recent studies. J Neural Transm 43: 209–215PubMedCrossRefGoogle Scholar
  38. Sandler M, Glover V, Ashford A, Esfaiail A (1980) The inhibition of tyramine oxidation and the tyramine hypertensive response (“cheese effect”) may be independent phenomena. J Neural Transm 48: 241–247PubMedCrossRefGoogle Scholar
  39. Schacter M, Marsden CD, Parkes JD, Jenner P, Testa B (1980) Deprenyl in the management of response fluctuations in patients with Parkinson’s disease on levodopa. J Neurol Neurosurg Psychiatry 43: 1016–21CrossRefGoogle Scholar
  40. Stern GM, Lees AJ, Sandler M (1978) Recent observations on the clinical pharmacology of deprenyl. J Neural Transm 43: 245–251PubMedCrossRefGoogle Scholar
  41. Yahr MD (1976) Evaluation of long term therapy in Parkinson’s disease: mortality and therapeutic efficacy. In: Birkmayer W, Horneykiewicz O (eds) Advances in parkinsonism. Roche, Basel pp 435–444Google Scholar
  42. Yahr MD (1978) Overview of present day treatment of Parkinson’s disease. J Neural Transm 43: 227–238PubMedCrossRefGoogle Scholar
  43. Yahr MD (1984) Limitations of long term use of antiparkinson drugs. Can J Neurol Sci 2: 191–194Google Scholar
  44. Yahr MD, Duvoisin R (1972) Drug therapy of parkinsonism. N Engl J Med 287: 20–24PubMedCrossRefGoogle Scholar
  45. Yahr MD, Mendoza MR, Moros D, Bergmann KJ (1983) Treatment of Parkinson’s disease in early and late phases. Use of pharmacological agents with special reference to deprenyl (selegiline), Acta Neurol Scand [Suppl] 95: 95–102CrossRefGoogle Scholar
  46. Youdim MBH (1978) The active centers of monoamine oxidase type “A” and “B”: binding with [14C] clorgyline and [14C] deprenyl. J Neural Transm 43: 199–208PubMedCrossRefGoogle Scholar
  47. Youdim MBH, Collins GGS, Sandler M, Jones Bevan AB, Pare CMB, Nicholson WJ (1972) Human brain monoamine oxidase, multiple forms and selective inhibitors. Nature 236: 225–228PubMedCrossRefGoogle Scholar
  48. Zeller AA, Barsky J (1952) In vivo inhibition of liver and brain monoamine oxidase by l-isonicotinyl-2-isopropylhydrazine. Proc Soc Exp Biol Med 81: 459PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • M. D. Yahr
  • H. Kaufmann

There are no affiliations available

Personalised recommendations